The optimal time interval between the end of neoadjuvant systemic therapy (NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit of primary chemotherapy. The aim of this study is to evaluate the relationship between time to surgery (TTS) and survival outcomes.

Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients / Omarini, Claudia; Guaitoli, Giorgia; Noventa, Silvia; Andreotti, Alessia; Gambini, Anna; Palma, E; Papi, Simona; Tazzioli, Giovanni; Balduzzi, Sara; Dominici, Massimo; Cascinu, Stefano; Piacentini, Federico. - In: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. - ISSN 0748-7983. - (2016), pp. 1-6. [10.1016/j.ejso.2016.09.020]

Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients

CASCINU, Stefano;
2016-01-01

Abstract

The optimal time interval between the end of neoadjuvant systemic therapy (NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit of primary chemotherapy. The aim of this study is to evaluate the relationship between time to surgery (TTS) and survival outcomes.
2016
Breast cancer; Neoadjuvant chemotherapy; Time to surgery; pCR
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/108507
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 45
social impact